Quantcast

Latest Anthrax Stories

Drugs, DNA And Disease Discovered On Our Dollar Bills
2014-04-24 07:32:44

Lawrence LeBlond for redOrbit.com - Your Universe Online With as much money that is being exchanged on a daily basis it may concern most people to know that they are not only transferring paper from one hand to the next, but potentially thousands of microbes along with it. Researchers from New York University’s Center for Genomics and Systems Biology have found that those greenbacks in our wallets do not only contain trace amounts of cocaine and other drugs, as has been previously...

2014-04-08 08:32:45

Appoints Larry Gyenes, Formerly of Columbia Laboratories, as Chief Financial Officer PINE BROOK, N.J., April 8, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing process for ETI-204, an anthrax antitoxin currently undergoing Phase 3 clinical trials in healthy volunteers....

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-10 12:25:52

PINE BROOK, N.J., March 10, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/076,082, granting a patent which covers methods of preventing or treating anthrax with ETI-204, the company's anti-anthrax antibody, together with antibiotics. The patent also...

Taxonomy Boris Vinatzer
2014-02-24 04:45:12

redOrbit Staff & Wire Reports - Your Universe Online A new naming system proposed by one Virginia Tech scientist proposes moving beyond the current biological naming system and supplementing it with a new classification method based on an organism’s genome sequence. The new method was developed by Boris Vinatzer, an associate professor in the College of Agriculture and Life Science's Department of Plant Pathology, Physiology, and Weed Science, and he believes that it will create a...

2014-02-05 12:28:03

Over 400 subjects participating in phase 3 studies PINE BROOK, N.J., Feb. 5, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability...

2014-02-04 23:26:11

Grime Busters and Amazing! NOK OUT™ is on a mission to educate consumers and eradicate disease-causing organisms. At 2,000 PPM, NOK OUT™ is a serious contender in the battle against these threatening adversaries. Gaylord, MI (PRWEB) February 04, 2014 The most resistant organism in the healthcare environment is the bacterial spore. Bacterial spores serve largely as a resting, or dormant, stage in the bacterial life cycle, serving to reserve the bacterium through periods of unfavorable...

2014-02-04 12:28:56

HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million. Under...

2014-01-29 08:23:33

The ability to remediate buildings following a weaponized biological attack may have been achieved with AsepticSure® SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Medizone International, Inc. (The Company) (MZEI:OB, MZEI:QB) has just been granted its fourth patent for its revolutionary enclosed space room disinfection system, AsepticSure. The United States Patent and Trademark Office has issued US Patent number 8,636,951 titled BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN...


Latest Anthrax Reference Libraries

11_ca5cd45b16f3d4936fde0520fef6557b
2011-04-14 14:43:25

Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...

More Articles (1 articles) »
Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.